Introducing Nerivio: A Wearable Device for Migraine Management by Dr Reddy’s

Dr Reddy’s Laboratories, based in New Delhi, recently announced the launch of a wearable therapy device designed for drug-free management of migraine. The product, known as Nerivio, has received approval from the US Food and Drug Administration (USFDA), marking a significant advancement in migraine treatment options.

Non-Invasive Migraine Management

Nerivio is a prescription-based non-invasive device specifically developed for both acute and prophylactic (preventive) treatment of migraine in individuals aged 12 years and above. It provides an alternative to traditional medication by offering a drug-free approach to managing migraine symptoms.

Usage and Effectiveness

The device is designed to be worn on the upper arm and is recommended for use within 60 minutes of the onset of a migraine headache for acute treatment. Additionally, it can be used every alternate day for the prevention of migraines, providing patients with flexibility in managing their condition.

Digital Therapeutics Advancement

According to MV Ramana, CEO Branded Markets (India and Emerging Markets) at Dr Reddy’s, the introduction of Nerivio signifies the company’s foray into digital therapeutics. This area of healthcare is gaining popularity among physicians and patients due to its potential to reduce reliance on medication and improve outcomes for chronic or challenging-to-treat conditions.

Meeting Clinical Needs

Dr Reddy’s believes that Nerivio addresses a significant clinical need among migraine patients by offering a novel approach to migraine management. The device’s non-invasive nature and convenience make it an attractive option for individuals seeking effective migraine relief.

Expansion and Commercial Distribution

In addition to its launch in the United States, Dr Reddy’s has secured an exclusive agreement for the commercial marketing and distribution of Nerivio in several European countries. This strategic move reflects the company’s commitment to making innovative migraine management solutions accessible to a broader population.

As of the latest trading update, Dr Reddy’s shares have seen a positive response, demonstrating the market’s interest and confidence in Nerivio and the company’s strategic initiatives in healthcare innovation.